Stocks Health care REGN
NASDAQ · Health careRegeneron Pharmaceuticals, Inc. (REGN)
Regeneron Pharmaceuticals, Inc. brought in $15.5B of revenue over the twelve months to June 30, 2026, up 9.3% from a year earlier. Net income was $4.3B, a net margin of 27.9%. Operating cash flow minus capital spending left $4.1B of free cash flow in fiscal 2025. At June 30, 2026 it held $2.5B in cash against $2B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on July 30, 2026.
Key facts about Regeneron Pharmaceuticals, Inc.
- Net worth
- Regeneron Pharmaceuticals, Inc. has a market value (market cap) of $74.8B at the latest share price, and shareholders' equity of $31.7B on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $14.3B (+1.0% year on year), with net income of $4.5B. Over the 12 months to June 30, 2026: revenue $15.5B, net income $4.3B.
- Cash flow
- In fiscal 2025 operations brought in $5B of cash; after $898.4M of capital spending, free cash flow was $4.1B.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on July 30, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Regeneron Pharmaceuticals, Inc.'s next report was expected around October 5, 2026 and is not on file with the SEC yet.
What Regeneron Pharmaceuticals, Inc. does
Regeneron Pharmaceuticals discovers, develops, and manufactures medicines for people with serious diseases. Its products treat conditions such as eye diseases, allergic and inflammatory conditions, cancer, and cardiovascular disease. The company sells its prescription drugs to healthcare providers, pharmacies, and distributors. Its shares trade on NASDAQ under the ticker REGN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $14.3B | $4.5B | $41.48 | $4.1B |
| 2024 | $14.2B | $4.4B | $38.34 | $3.7B |
| 2023 | $13.1B | $4B | $34.77 | $3.9B |
| 2022 | $12.2B | $4.3B | $38.22 | $4.4B |
| 2021 | $16.1B | $8.1B | $71.97 | $6.5B |
| 2020 | $8.5B | $3.5B | $30.52 | $2B |
Full financial statements: income, balance sheet and cash flow
Where REGN ranks in Health care
Dividends
It paid out $370.3M in cash dividends, 8% of its net income.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2025 | n/a | $370.3M | 8% |
| 2024 | n/a | $0 | 0% |
| 2023 | n/a | $0 | 0% |
Latest SEC filings
What Regeneron Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 30, 2026Executive or director change8-KRegeneron granted one-time 10-year performance share unit awards to its CEO and CSO replacing annual equity awards until 2036.
- August 20, 2026Form N-PX filing N-PX
- August 7, 2026Form 13F-HR filing 13F-HR
- July 30, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 17% to $4.3B versus the same quarter last year; diluted EPS $12.23 versus $12.81.
- July 30, 2026
- July 6, 2026
- June 17, 2026
- May 8, 2026Form 13F-HR filing 13F-HR
- April 30, 2026Passive stake (5% or more) SCHEDULE 13G
- April 29, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 19% to $3.6B versus the same quarter last year; diluted EPS $6.75 versus $7.27.
What is REGN worth? A DCF from its reported cash flow
Insider trades
What the people running Regeneron Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $3.3M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 3, 2026 | McCourt MarionEVP Commercial | Soldpre-planned (10b5-1) | 1,131 | $969.7K |
| September 2, 2026 | McCourt MarionEVP Commercial | Soldpre-planned (10b5-1) | 1,215 | $1M |
| September 2, 2026 | Guarini KathrynDirector | Exercised options | 400 | $287.7K |
| September 2, 2026 | Guarini KathrynDirector | Soldpre-planned (10b5-1) | 400 | $340K |
| August 19, 2026 | Larosa Joseph JEVP General Counsel and Secret | Exercised options | 12,282 | $4.7M |
| August 19, 2026 | Larosa Joseph JEVP General Counsel and Secret | Shares withheld for tax | 9,019 | $7.5M |
| August 18, 2026 | Fenimore Christopher R.EVP Finance CFO | Exercised options | 6,283 | $2.4M |
| August 18, 2026 | Fenimore Christopher R.EVP Finance CFO | Shares withheld for tax | 4,599 | $3.7M |
Who owns REGN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Vanguard Capital Management13G, passive | 7.37% | April 30, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 1,332 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 9,113,506 | +165,771 |
| Vanguard Capital Management LLC | 6,629,759 | -25,154 |
| Dodge & Cox | 4,871,137 | +412,899 |
| State Street Corp | 4,834,688 | +170,210 |
| Invesco Ltd. | 3,940,665 | +35,556 |
| Jpmorgan Chase & Co | 3,774,199 | -537,607 |
| Vanguard Portfolio Management LLC | 3,175,313 | +1,454,539 |
| Franklin Resources Inc | 2,771,839 | +49,768 |
| Geode Capital Management, LLC | 2,625,810 | +18,078 |
| Nuveen, LLC | 2,019,974 | -45,090 |
| Loomis Sayles & Co L P | 1,859,172 | -53,138 |
| PeakShares LLC | 1,564 | +114 |
| Morgan Stanley | 1,397,712 | +78,383 |
| Bank of America Corp | 1,291,053 | +101,469 |
| Wellington Management Group Llp | 1,270,087 | -567,372 |
| Norges Bank | 1,172,808 | new |
| Goldman Sachs Group Inc | 1,163,191 | -137,367 |
| Aqr Capital Management LLC | 1,126,080 | -104,928 |
| Amundi | 1,013,540 | +3,742 |
| Northern Trust Corp | 916,467 | -25,474 |
Insiders
19 insiders reported holding 736,157 shares in total, about $534.8M at the last price.
| Holder | Shares |
|---|---|
| Yancopoulos GeorgeBd. Co-Chair, President & CSO, Director | 310,460 |
| Schleifer Leonard SBd. Co-Chair, President & CEO, Director | 214,523 |
| Murphy Andrew JEVP Research | 47,833 |
| Larosa Joseph JEVP General Counsel and Secret | 36,373 |
| Sing George LDirector | 31,007 |
| Van Plew Daniel PEVP & General Mgr, Industrial | 21,673 |
| Fenimore Christopher R.EVP Finance CFO | 19,984 |
| Ryan Arthur FDirector | 17,303 |
| McCourt MarionEVP Commercial | 12,003 |
| Goldstein Joseph LDirector | 6,703 |
Questions about REGN
What does Regeneron Pharmaceuticals, Inc. do?
Regeneron Pharmaceuticals discovers, develops, and manufactures medicines for people with serious diseases. Its products treat conditions such as eye diseases, allergic and inflammatory conditions, cancer, and cardiovascular disease. The company sells its prescription drugs to healthcare providers, pharmacies, and distributors. Its shares trade on NASDAQ under the ticker REGN.
What is Regeneron Pharmaceuticals, Inc.'s net worth?
Regeneron Pharmaceuticals, Inc. has a market value (market cap) of $74.8B at the latest share price, and shareholders' equity of $31.7B on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Regeneron Pharmaceuticals, Inc. profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $4.3B on revenue of $15.5B, a net margin of 27.9%.
How much revenue does Regeneron Pharmaceuticals, Inc. make?
Over the twelve months to June 30, 2026 Regeneron Pharmaceuticals, Inc. reported revenue of $15.5B. That is 9.3% more than a year earlier.
When did Regeneron Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on July 30, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the executive or director change from September 30, 2026.
When is Regeneron Pharmaceuticals, Inc.'s next earnings report?
Regeneron Pharmaceuticals, Inc.'s next report was expected around October 5, 2026 and is not on file with the SEC yet.
Similar companies
Compare REGN with
Follow REGN
Get an email when Regeneron Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow REGN: get an email when it filesWhere the numbers come from
Financial figures are the values Regeneron Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.